


1. (currently amended) A compound of the formula I,



in which

W, X, Y are, independently of one another, O or S;

R9, R10, R11, R12 are, independently of one another, H, F, Cl, Br, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, O-SO<sub>2</sub>-phenyl, where the phenyl ring may be substituted up to twice by F, Cl, Br, CN, OR13, R13, CF<sub>3</sub>, OCF<sub>3</sub>, COOR13 or CON(R14)(R15), or S-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, S-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, SO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-NH<sub>2</sub>, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOR13, CON(R14)(R15), (C<sub>0</sub>-C<sub>6</sub>)-alkylene-N(R14)(R15), NH-COR13, NH-CO-phenyl, NH-SO<sub>2</sub>-phenyl or phenyl, where the phenyl ring may be substituted up to twice by F, Cl, Br, CN, OR13, R13, CF<sub>3</sub>, OCF<sub>3</sub>, COOR13 or CON(R14)(R15);

R13 is H, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl or (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>4</sub>)-alkyl;

R1, R2 are, independently of one another, H, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, where alkyl may be substituted by OH, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl or N(R14)(R15), or O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, CO-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, COOR13 or (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOR13;

R3, R4, R5, R6 are, independently of one another, H, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>10</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>10</sub>)-alkenyl, O-(C<sub>2</sub>-C<sub>10</sub>)-alkynyl, S-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, S-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)-

cycloalkyl-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, where alkyl, alkenyl, alkynyl and cycloalkyl may be substituted more than once by F, Cl, Br, SO-phenyl, SO<sub>2</sub>-phenyl, where the phenyl ring may be substituted by F, Cl, Br or R13, or OR13, COOR13, CON(R14)(R15), N(R14)(R15) or CO-heteroalkyl, or are O-SO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-SO<sub>2</sub>-(C<sub>6</sub>-C<sub>10</sub>)-aryl, O-(C<sub>6</sub>-C<sub>10</sub>)-aryl, where aryl may be substituted up to twice by F, Cl, CN, OR13, R13, CF<sub>3</sub> or OCF<sub>3</sub>, or are SO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>6</sub>-C<sub>10</sub>)-aryl, where the phenyl ring may be substituted up to twice by F, Cl, Br, CN, OR13, R13, CF<sub>3</sub>, OCF<sub>3</sub>, COOR13 or CON(R14)(R15), or are SO<sub>2</sub>-N(R14)(R15), COOR13, CO-heteroalkyl, N(R14)(R15) or heteroalkyl;

R14, R15 are, independently of one another, H, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, where alkyl may be substituted by N(R13)<sub>2</sub>, or are (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkylene-OCO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-phenyl, COO-phenyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkenyl-phenyl, OH, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkenyl-phenyl or NH<sub>2</sub>;

or the radicals R14 and R15 form with the nitrogen atom to which they are bonded a 3-7-membered, saturated heterocyclic ring which may comprise up to 2 further heteroatoms from the group of N, O or S, where the heterocyclic ring may be substituted up to three times by F, Cl, Br, OH, oxo, N(R16)(R17) or (C<sub>1</sub>-C<sub>4</sub>)-alkyl;

R16, R17 are, independently of one another, H, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, where alkyl may be substituted by N(R13)<sub>2</sub>, or are (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkylene-OCO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-phenyl, COO-phenyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkenyl-phenyl, OH, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkenyl-phenyl or NH<sub>2</sub>;

heteroalkyl is a 3-7-membered, saturated or up to triunsaturated heterocyclic ring which may comprise up to 4 heteroatoms which correspond to N, O or S, where the heterocyclic ring may be substituted at all sensible positions up to three times by F, Cl, Br, CN, oxo, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>0</sub>-C<sub>4</sub>)-alkylene-COOR13, CON(R14)(R15), OR13, N(R14)(R15) or phenyl, where phenyl may be substituted by COOR13;

R7 is H, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, where alkyl may be substituted by OR13 or N(R14)(R15), or is O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOR13;

R8        is N(R18)(R19);

R18, R19    are, independently of one another, H, (C<sub>1</sub>-C<sub>10</sub>)-alkyl, (C<sub>2</sub>-C<sub>10</sub>)-alkenyl, (C<sub>2</sub>-C<sub>10</sub>)-alkynyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>6</sub>-C<sub>10</sub>)-aryl, (C<sub>6</sub>-C<sub>10</sub>)-aryl-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>6</sub>-C<sub>10</sub>)-aryl-(C<sub>2</sub>-C<sub>4</sub>)-alkenyl, (C<sub>6</sub>-C<sub>10</sub>)-aryl-(C<sub>2</sub>-C<sub>4</sub>)-alkynyl, heteroaryl, heteroaryl-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, heteroaryl-(C<sub>2</sub>-C<sub>4</sub>)-alkenyl, heteroaryl-(C<sub>2</sub>-C<sub>4</sub>)-alkynyl, where alkyl, alkenyl, alkynyl and cycloalkyl may be substituted more than once by F, Cl, CN, OR13, R13, CF<sub>3</sub>, OCF<sub>3</sub>, (C<sub>6</sub>-C<sub>10</sub>)-aryl, NH-C(=NR14)-N(R14)(R15), N(R14)(R15), C(=NR14)-N(R14)(R15), COOR13 or CON(R14)(R15), and where aryl may be substituted more than once by F, Cl, CN, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, where alkyl and alkenyl may be substituted more than once by F, Cl, CH<sub>3</sub>, OCH<sub>3</sub> or CN, or NH-C(=NR14)-N(R14)(R15), N(R14)(R15), C(=NR14)-N(R14)(R15), COOR13, CON(R14)(R15), O-phenyl, phenyl or pyridyl; COOR13, CON-(R14)(R15), CO-heteroalkyl, CO-(C<sub>6</sub>-C<sub>10</sub>)-aryl or SO<sub>2</sub>-(C<sub>6</sub>-C<sub>10</sub>)-aryl, where aryl may be substituted up to twice by F, Cl, CN, OH, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CF<sub>3</sub>, OCF<sub>3</sub>, COOR13 or CON(R14)(R15);

or the radicals R18 and R19 form with the nitrogen atom to which they are bonded a 3-7-membered, saturated heterocyclic ring which may comprise up to 2 further heteroatoms from the group of N, O or S, where the heterocyclic ring may be substituted up to three times by F, Cl, Br, OH, oxo, N(R16)(R17) or (C<sub>1</sub>-C<sub>4</sub>)-alkyl;

or a pharmaceutically acceptable salt thereof,

provided the radicals R3, R4, R5, R6, R7, X, Y and R8 do not have the following meanings at the same time:

R3, R4 or R5 is CF<sub>3</sub>;

R6        is H or CF<sub>3</sub>;


R7        is H;

X        is O; and

Y        is O, S;

R8        is substituted or unsubstituted NH-phenyl wherein either the nitrogen atom or the phenyl ring is substituted or unsubstituted.

2. (previously presented) A compound of the formula I as claimed in claim 1, wherein said compound has the structure of compound Ia:



Ia

wherein

R9 is F, Cl, Br, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, O-SO<sub>2</sub>-phenyl, where the phenyl ring may be substituted up to twice by F, Cl, Br, CN, OR13, R13, CF<sub>3</sub>, OCF<sub>3</sub>, COOR13 or CON(R14)(R15), or S-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, S-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, SO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-NH<sub>2</sub>, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, -COOR13, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOR13, CON(R14)(R15), -N(R14)(R15), (C<sub>1</sub>-C<sub>6</sub>)-alkylene-N(R14)(R15), NH-COR13, NH-CO-phenyl, NH-SO<sub>2</sub>-phenyl or phenyl, where the phenyl ring may be substituted up to twice by F, Cl, Br, CN, OR13, R13, CF<sub>3</sub>, OCF<sub>3</sub>, COOR13 or CON(R14)(R15);

R10, R11, R12 independently of one another are H, F, Cl, Br, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, O-SO<sub>2</sub>-phenyl, where the phenyl ring may be substituted up to twice by F, Cl, Br, CN, OR13, R13, CF<sub>3</sub>, OCF<sub>3</sub>, COOR13 or CON(R14)(R15), or S-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, S-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, SO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-NH<sub>2</sub>, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, COOR13, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOR13, CON(R14)(R15), N(R14)(R15), (C<sub>1</sub>-C<sub>6</sub>)-alkylene-N(R14)(R15), NH-COR13, NH-CO-phenyl, NH-SO<sub>2</sub>-phenyl or phenyl, where the phenyl ring may be substituted up to twice by F, Cl, Br, CN, OR13, R13, CF<sub>3</sub>, OCF<sub>3</sub>, COOR13 or CON(R14)(R15);

- R13 is H, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl or (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>4</sub>)-alkyl;
- R3, R4, R5, are independently of one another H, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>10</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>10</sub>)-alkenyl, O-(C<sub>2</sub>-C<sub>10</sub>)-alkynyl, S-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, S-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, where alkyl, alkenyl, alkynyl and cycloalkyl may be substituted more than once by F, Cl, Br, SO-phenyl, SO<sub>2</sub>-phenyl, where the phenyl ring may be substituted by F, Cl, Br or R13, or OR13, COOR13, CON(R14)(R15), N(R14)(R15) or CO-heteroalkyl, or O-SO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-SO<sub>2</sub>-(C<sub>6</sub>-C<sub>10</sub>)-aryl, O-(C<sub>6</sub>-C<sub>10</sub>)-aryl, where aryl may be substituted up to twice by F, Cl, CN, OR13, R13, CF<sub>3</sub> or OCF<sub>3</sub>, or SO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>6</sub>-C<sub>10</sub>)-aryl, where the phenyl ring may be substituted up to twice by F, Cl, Br, CN, OR13, R13, CF<sub>3</sub>, OCF<sub>3</sub>, COOR13 or CON(R14)(R15), or SO<sub>2</sub>-N(R14)(R15), COOR13, CO-heteroalkyl, N(R14)(R15) or heteroalkyl;
- R6 is OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>10</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>10</sub>)-alkenyl, O-(C<sub>2</sub>-C<sub>10</sub>)-alkynyl, S-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, S-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, where alkyl, alkenyl, alkynyl and cycloalkyl may be substituted more than once by F, Cl, Br, SO-phenyl, SO<sub>2</sub>-phenyl, where the phenyl ring may be substituted by F, Cl, Br or R13, or OR13, COOR13, CON(R14)(R15), N(R14)(R15) or CO-heteroalkyl, or O-SO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-SO<sub>2</sub>-(C<sub>6</sub>-C<sub>10</sub>)-aryl, O-(C<sub>6</sub>-C<sub>10</sub>)-aryl, where aryl may be substituted up to twice by F, Cl, CN, OR13, R13, CF<sub>3</sub> or OCF<sub>3</sub>, or SO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>6</sub>-C<sub>10</sub>)-aryl, where the phenyl ring may be substituted up to twice by F, Cl, Br, CN, OR13, R13, CF<sub>3</sub>, OCF<sub>3</sub>, COOR13 or CON(R14)(R15), or SO<sub>2</sub>-N(R14)(R15), COOR13, CO-heteroalkyl, N(R14)(R15) or heteroalkyl;
- R14, R15 independently of one another are H, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, where alkyl may be substituted by N(R13)<sub>2</sub>, or (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkylene-O-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-phenyl, COO-phenyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkenyl-phenyl, OH, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkenyl-phenyl or NH<sub>2</sub>;

or the radicals R14 and R15 form with the nitrogen atom to which they are bonded a 3-7-membered, saturated heterocyclic ring which may comprise up to 2 further heteroatoms from the

group of N, O or S, where the heterocyclic ring may be substituted up to three times by F, Cl, Br, OH, oxo, N(R16)(R17) or (C<sub>1</sub>-C<sub>4</sub>)-alkyl;

R16, R17	independently of one another are H, (C <sub>1</sub> -C <sub>6</sub> )-alkyl, where alkyl may be substituted by N(R13) <sub>2</sub> , or (C <sub>2</sub> -C <sub>6</sub> )-alkenyl, (C <sub>2</sub> -C <sub>6</sub> )-alkynyl, (C <sub>3</sub> -C <sub>7</sub> )-cycloalkyl, (C <sub>3</sub> -C <sub>7</sub> )-cycloalkyl-(C <sub>1</sub> -C <sub>4</sub> )-alkyl, CO-(C <sub>1</sub> -C <sub>6</sub> )-alkyl, COO-(C <sub>1</sub> -C <sub>6</sub> )-alkyl, COO-(C <sub>1</sub> -C <sub>6</sub> )-alkylene-OCO-(C <sub>1</sub> -C <sub>6</sub> )-alkyl, CO-phenyl, COO-phenyl, COO-(C <sub>1</sub> -C <sub>6</sub> )-alkenyl-phenyl, OH, O-(C <sub>1</sub> -C <sub>6</sub> )-alkyl, O-(C <sub>1</sub> -C <sub>6</sub> )-alkenyl-phenyl or NH <sub>2</sub> ;
heteroalkyl	is a 3-7-membered, saturated or up to triunsaturated heterocyclic ring which may comprise up to 4 heteroatoms selected from N, O or S, where the heterocyclic ring may be substituted up to three times by F, Cl, Br, CN, oxo, (C <sub>1</sub> -C <sub>4</sub> )-alkyl, COOR13, (C <sub>1</sub> -C <sub>4</sub> )-alkylene-COOR13, CON(R14)(R15), OR13 or N(R14)(R15) or phenyl, where phenyl may be substituted by COOR13;
R8	is N(R18)(R19);
R18, R19	independently of one another are H, (C <sub>1</sub> -C <sub>10</sub> )-alkyl, (C <sub>2</sub> -C <sub>10</sub> )-alkenyl, (C <sub>2</sub> -C <sub>10</sub> )-alkynyl, (C <sub>3</sub> -C <sub>7</sub> )-cycloalkyl, (C <sub>3</sub> -C <sub>7</sub> )-cycloalkyl-(C <sub>1</sub> -C <sub>6</sub> )-alkyl, (C <sub>6</sub> -C <sub>10</sub> )-aryl, (C <sub>6</sub> -C <sub>10</sub> )-aryl-(C <sub>1</sub> -C <sub>4</sub> )-alkyl, (C <sub>6</sub> -C <sub>10</sub> )-aryl-(C <sub>2</sub> -C <sub>4</sub> )-alkenyl, (C <sub>6</sub> -C <sub>10</sub> )-aryl-(C <sub>2</sub> -C <sub>4</sub> )-alkynyl, heteroaryl, heteroaryl-(C <sub>1</sub> -C <sub>4</sub> )-alkyl, heteroaryl-(C <sub>2</sub> -C <sub>4</sub> )-alkenyl, heteroaryl-(C <sub>2</sub> -C <sub>4</sub> )-alkynyl, where alkyl, alkenyl, alkynyl and cycloalkyl may be substituted more than once by F, Cl, CN, OR13, R13, CF <sub>3</sub> , OCF <sub>3</sub> , (C <sub>6</sub> -C <sub>10</sub> )-aryl, NH-C(=NR14)-N(R14)(R15), N(R14)(R15), C(=NR14)-N(R14)(R15), COOR13 or CON(R14)(R15), and where aryl may be substituted more than once by F, Cl, CN, O-(C <sub>1</sub> -C <sub>6</sub> )-alkyl, O-(C <sub>2</sub> -C <sub>6</sub> )-alkenyl, (C <sub>1</sub> -C <sub>6</sub> )-alkyl, (C <sub>2</sub> -C <sub>6</sub> )-alkenyl, CO-(C <sub>1</sub> -C <sub>6</sub> )-alkyl, CO-(C <sub>2</sub> -C <sub>6</sub> )-alkenyl, where alkyl and alkenyl may be substituted more than once by F, Cl, CH <sub>3</sub> , OCH <sub>3</sub> or CN, or NH-C(=NR14)-N(R14)(R15), N(R14)(R15), C(=NR14)-N(R14)(R15), COOR13, CON(R14)(R15), O-phenyl, phenyl or pyridyl; COOR13, CON-(R14)(R15), CO-heteroalkyl, CO-(C <sub>6</sub> -C <sub>10</sub> )-aryl or SO <sub>2</sub> -(C <sub>6</sub> -C <sub>10</sub> )-aryl, where aryl may be substituted up to twice by F, Cl, CN, OH, (C <sub>1</sub> -C <sub>6</sub> )-alkyl, O-(C <sub>1</sub> -C <sub>6</sub> )-alkyl, CF <sub>3</sub> , OCF <sub>3</sub> , COOR13 or CON(R14)(R15);

or the radicals R18 and R19 form together with the nitrogen atom to which they are bonded a 3-7-membered, saturated heterocyclic ring which may comprise up to 3 heteroatoms

selected from the group of N, O or S, where the heterocyclic ring may be substituted up to three times by F, Cl, Br, OH, oxo, N(R16)(R17) or (C<sub>1</sub>-C<sub>4</sub>)-alkyl;

or a pharmaceutically acceptable salt thereof,

provided the radical R8 is not substituted or unsubstituted NH-phenyl wherein either the nitrogen atom or the phenyl ring is substituted or unsubstituted.

3. (previously presented) A compound of the formula Ia as claimed in claim 2, wherein

R9, R10, R11 independently of one another are F or Cl;

R12 is H;

R13 is H, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl or (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>4</sub>)-alkyl;

R14, R15 independently of one another are H or (C<sub>1</sub>-C<sub>6</sub>)-alkyl, where alkyl may be substituted by N(R13)<sub>2</sub>;

heteroalkyl is a 3-7-membered, saturated or up to triunsaturated heterocyclic ring which may comprise up to 4 heteroatoms selected from N, O or S, where the heterocyclic ring may be substituted up to three times by F, Cl, Br, CN, oxo, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, COOR13, (C<sub>1</sub>-C<sub>4</sub>)-alkylene-COOR13, CON(R14)(R15), OR13 or N(R14)(R15) or phenyl, where phenyl may be substituted by COOR13;

R8 is N(R18)(R19);

R18, R19 independently of one another are H, (C<sub>1</sub>-C<sub>10</sub>)-alkyl, (C<sub>2</sub>-C<sub>10</sub>)-alkenyl, (C<sub>2</sub>-C<sub>10</sub>)-alkynyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>6</sub>-C<sub>10</sub>)-aryl, (C<sub>6</sub>-C<sub>10</sub>)-aryl-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, (C<sub>6</sub>-C<sub>10</sub>)-aryl-(C<sub>2</sub>-C<sub>4</sub>)-alkenyl, (C<sub>6</sub>-C<sub>10</sub>)-aryl-(C<sub>2</sub>-C<sub>4</sub>)-alkynyl, heteroaryl, heteroaryl-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, heteroaryl-(C<sub>2</sub>-C<sub>4</sub>)-alkenyl, heteroaryl-(C<sub>2</sub>-C<sub>4</sub>)-alkynyl, where alkyl, alkenyl, alkynyl and cycloalkyl may be substituted more than once by F, Cl, CN, OR13, R13, CF<sub>3</sub>, OCF<sub>3</sub>, (C<sub>6</sub>-C<sub>10</sub>)-aryl, NH-C(=NR14)-N(R14)(R15), N(R14)(R15), C(=NR14)-N(R14)(R15), COOR13 or CON(R14)(R15), and where aryl may be substituted more than once by F, Cl, CN, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl,

(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, where alkyl and alkenyl may be substituted more than once by F, Cl, CH<sub>3</sub>, OCH<sub>3</sub> or CN, or NH-C(=NR14)-N(R14)(R15), N(R14)(R15), C(=NR14)-N(R14)(R15), COOR13, CON(R14)(R15), O-phenyl, phenyl or pyridyl; COOR13, CON-(R14)(R15), CO-heteroalkyl, CO-(C<sub>6</sub>-C<sub>10</sub>)-aryl or SO<sub>2</sub>-(C<sub>6</sub>-C<sub>10</sub>)-aryl, where aryl may be substituted up to twice by F, Cl, CN, OH, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CF<sub>3</sub>, OCF<sub>3</sub>, COOR13 or CON(R14)(R15);

or the radicals R18 and R19 form together with the nitrogen atom to which they are bonded a 3-7-membered, saturated heterocyclic ring which may comprise up to 3 heteroatoms selected from the group of N, O or S, where the heterocyclic ring may be substituted up to three times by F, Cl, Br, OH, oxo, N(R16)(R17) or (C<sub>1</sub>-C<sub>4</sub>)-alkyl.

4. (previously presented) A pharmaceutical composition comprising one or more of the compounds as claimed in claim 1 and an acceptable carrier.

5. (withdrawn) A pharmaceutical composition comprising one or more of the compounds as claimed in claim 1, an acceptable carrier, and at least one other active ingredient.

6. (withdrawn) A pharmaceutical composition as claimed in claim 5, wherein the other active ingredient comprises one or more antidiabetics, hypoglycemic active ingredients, HMG-CoA reductase inhibitors, cholesterol absorption inhibitors, PPAR gamma agonists, PPAR alpha agonists, PPAR alpha/gamma agonists, fibrates, MTP inhibitors, bile acid absorption inhibitors, CETP inhibitors, polymeric bile acid adsorbents, LDL receptor inducers, ACAT inhibitors, antioxidants, lipoprotein lipase inhibitors, ATP-citrate lyase inhibitors, squalene synthetase inhibitors, lipoprotein(a) antagonists, lipase inhibitors, insulins, sulfonylureas, biguanides, meglitinides, thiazolidinediones,  $\alpha$ -glucosidase inhibitors, active ingredients which act on the ATP-dependent potassium channel of the beta cells, CART agonists, NPY agonists, MC4 agonists, orexin agonists, H3 agonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists,  $\beta$ 3 agonists, MSH (melanocyte-stimulating hormone) agonists, CCK agonists, serotonin reuptake inhibitors, mixed serotonergic and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormones, growth hormone-releasing compounds, TRH agonists, decoupling protein 2 or 3 modulators, leptin agonists, DA agonists (bromocriptine, Doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modulators or TR- $\beta$  agonists or amphetamines.

7. (original) A process for producing a pharmaceutical composition comprising mixing one or more of the compounds as claimed in claim 1 with an active ingredient and a pharmaceutically suitable carrier and converting this mixture into a suitable for administration.
8. (withdrawn) A method for reducing blood glucose, comprising administering to a subject in need thereof, one or more compounds claimed in claim 1.
9. (withdrawn) A method for treating type 2 diabetes, comprising administering to a subject in need thereof, one or more compounds claimed in claim 1.
10. (withdrawn) A method for treating disturbances of lipid and carbohydrate metabolism, comprising administering to a subject in need thereof, one or more compounds claimed in claim 1.
11. (withdrawn) A method for treatin arteriosclerotic manifestations, comprising administering to a subject in need thereof, one or more compounds claimed in claim 1.
12. (withdrawn) A method for treating insulin resistance, comprising administering to a subject in need thereof, one or more compounds claimed in claim 1.